Custom Drugs May Be On the Horizon

Join Our Community of Science Lovers!

One promise of the Human Genome Project is that in the future, drug treatments will be tailored to individuals¿ needs. Indeed, physicians will be able to take into consideration how well a patient can handle a drug based on his or her genes. Now researchers are beginning to make good on this promise: in today¿s Nature Genetics, they describe how different versions of a single gene can modulate responses to many medicines.

In particular, they looked at a kind of cytochrome P450 (CYP) enzyme. These enzymes break up a large number of chemicals, including drugs and toxins, and remove them from the body. Humans have about 55 different CYP genes belonging to various families. And members of the CYP3A family metabolize such important drugs as HIV protease inhibitors, calcium channel blockers, cholesterol-lowering drugs and cancer chemotherapeutics. The catch is that the amount of CYP3A proteins in the liver and small intestine can differ a great deal from one person to the next.

Scientists from the U.S., the U.K. and France have now found the reason: alleles of gene CYP3A5 that sometimes differ in just one DNA base¿a so-called single nucleotide polymorphism (SNP)¿lead to vastly different amounts of protein CYP3A5. This enzyme breaks down many drugs, but it also activates aflatoxin B1, a carcinogen. Depending on the allele, some people make no CYP3A5 at all; others, high amounts. African-Americans and Southeast Asians are more likely than Europeans, Japanese or Mexicans to possess an allele that produces a lot of CYP3A5.

On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.

Thus, the allele can probably predict how well a person will respond to a drug. "Simple DNA-based tests can now be used to determine how individual differences in CYP3A5 contribute to the overall metabolic fate of these CYP3A substrates," the authors conclude in their paper.

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American